The aqueous stability of bupropion
Related Experiment Video
Updated: Jun 12, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Paul M O'Byrne1, Robert Williams, John J Walsh
1School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin 2, Ireland. obyrnep@tcd.ie
Abstract:
In this study the aqueous stability of bupropion was determined and the pH-degradation profile was obtained. The effects of hydrogen ion, solvent and hydroxide ion concentration are discussed with particular emphasis on the kinetics of degradation of bupropion. Kinetics and degradation of bupropion were determined by HPLC-UV and LC-MS analysis both utilising high pH chromatographic methods. Degradation of bupropion in aqueous solutions follows first-order reaction kinetics. The pH-degradation profile was determined using non-linear regression analysis. The micro- and macro-reaction constants for degradation are presented. Bupropion was most stable in aqueous solutions below pH 5. Degradation was catalyzed by water but mainly by hydroxide ion on the unionised form of bupropion. The energy of activation for decomposition in aqueous solution pH 10.7 I=0.055 was determined to be 53 kJ mol(-1) with a frequency factor of 6.43 x 10(10)s(-1). The degradants of bupropion were positively identified and a mechanism of degradation is proposed. The inherent instability of bupropion above pH 5 has implications for its therapeutic use, formulation, pharmacokinetics and use during analysis and storage.
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles in drug...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Biotransformation: Overview